Gland Pharma Ltd. · NSE:GLAND
Gland Pharma — Q3 FY2025 Earnings Presentation
17 slides from Gland Pharma's earnings presentation, Feb 3, 2025
Slide 1: Exchange filing cover letter for Investor Presentation
GLAND PHARMA LIMITED February 03, 2025 BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor 25thth floor, Dalal Street Plot no. C-1, C-l, Block G, Bandra Kurla Complex Bandra Mumbai - 400 001 (Ea
Slide 2: Investor Presentation Q3 & 9M FY25
GLANDI GLAND PHARMA — J I 1 Investor JL. Presentation Q3 & 9M FY25 03 February 2025
Slide 3: Safe Harbour Statement
Safe Harbour Statement The Presentation is to provide the general background information about the Company’s activities Company’s activities as as at at the the date date of of the the Presentation. Presentation. The The information information contained herein is for general information purposes on
Slide 4: Consolidated P&L Highlights
Consolidated P&L Highlights ₹ Mn Mn Particulars Q3 FY25 Q3 FY24 YoY Q2 FY25 QoQ 9M FY25 9M FY24 YoY Revenue from operations 13,841 15,452 -10% 14,058 -2% 41,916 41,273 2% Other Income 585 374 56% 596 -2% 1,696 1,281 32% Total Income 14,426 15,826 -9% 14,654 -2% 43,612 42,554 2% * Gross Profit (1) 9,
Slide 5: Consolidated Financial Highlights
Consolidated Financial Highlights * Revenue from Operations *1> / Gross Profit Margin & Gross Profit (1) (2) (₹ Mn) (< (₹ Mn / %) (< 1% 2% 25,536 25,892 41,273 41,916 62% 62% II -10% -3% 15,452 9,459 8,304 9,213 14,058 13,841 61% 67% 59% Q3 FY24 Q2 FY25 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q2 FY25 Q3 FY2
Slide 6: Base Business (Gland) Financial Highlights (1/2)
Base Business (Gland) Financial Highlights (1/2) Revenue from Operations 3% <1>// PAT / PAT Margin & EBITDA Margin (1) (2) (₹ (? Mn) Mn) (₹ (? Mn Mn // %) %) 3 3 o/o 33% 34% 30,032 30,917 7,955 7,296 26% -8% -8% 34% 34% 39% 24% —► 11,013 10,659 10,123 2,808 2,843 2,864 25% 27% 28% Q3 FY24 Q2 FY25 Q3
Slide 7: Base Business (Gland) Financial Highlights (2/2)
Base Business (Gland) Financial Highlights (2/2) ₹ Mn Mn Particulars Q3 FY25 Q3 FY24 YoY Q2 FY25 QoQ 9M FY25 9M FY24 YoY Revenue from operations 10,123 11,013 -8% 10,659 -5% 30,917 30,032 3% Gross Profit 6,357 6,128 4% 5,957 7% 17,663 16,996 4% % margin 63% 56% 56% 57% 57% EBITDA 3,911 3,727 5% 3,64
Slide 8: Cenexi Performance
Cenexi Performance Q3 FY25 Q3 FY24 Q2 FY25 9M FY25 9M FY24* Particulars YoY QoQ YoY € Mn. € Mn. ₹ Mn. ?Mn. € € Mn. Mn. ₹ Mn. ?Mn. € Mn. € Mn. ₹ Mn. ?Mn. € € Mn. Mn. ₹ Mn. ?Mn. € € Mn. Mn. ₹ Mn. ?Mn. Revenue from 41 3,717 50 4,439 -16% 37 3,399 9% 121 10,999 125 11,240 -2% operations Gross Profit 32
Slide 9: Geographical Revenue Mix
GLAND Geographical Revenue Mix
Slide 10: US Market
US Market ₹<Mn Mn Group Group Revenue Contribution Gland Cenexi 4% YoY 5% YoY -23% YoY -11% YoY -12% YoY 5% YoY 21,591 22,469 21,053 22,052 22,052 538 417 8,216 7,547 7,293 8,065 7,393 7,135 151 154 158 Q3 FY24 Q2 FY25 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q2 FY25 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q2 FY25 Q
Slide 11: Europe Market
Europe Market ₹I MMn n Group Revenue Contribution Gland Cenexi -19% YoY -4% YoY 30% YoY 7% YoY -5% YoY -24% YoY 1,079 1,155 1 155 ’ 7,963 7,672 6,884 6,517 3,251 Q3 FY24 2,459 Q2 FY25 2,646 Q3 FY25 9M FY24 9M FY25 323 Q3 FY24 329 Q2 FY25 419 Q3 FY25 11 9M FY24 9M FY25 2,928 Q3 FY24 2,130 Q2 FY25 2,2
Slide 12: Other Core Markets (Canada, Australia and New Zealand)
Other Core Markets (Canada, Australia and New Zealand) ₹ Mn Group Revenue Contribution Gland Cenexi 20% YoY 42% YoY 37% YoY 16% YoY 34% YoY 53% YoY 937 1,420 683 483 998 405 338 315 514 459 292 382 121 90 109 Q3 FY24 Q2 FY25 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q2 FY25 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q2
Slide 13: Rest of the World
Rest of the World ₹ Mn Group Revenue Contribution Gland Cenexi 1% YoY -1% YoY 6% YoY -3% YoY -5% YoY 2% YoY 4,934 4,810 8,437 8,392 3,503 3,582 2,842 Q3 FY24 2,663 Q2 FY25 2,881 Q3 FY25 9M FY24 9M FY25 1,573 Q3 FY24 1,658 Q2 FY25 1,669 Q3 FY25 II 9M FY24 9M FY25 1,269 Q3 FY24 1,005 Q2 FY25 1,212 Q3
Slide 14: India
India ₹ Mn Gland India Contribution to the Group Business Update -26% YoY -14% YoY 4% Revenue declined due to a decrease in 2,283 volume 1,963 9MFY25 761 874 562 Q3 FY24 Q2 FY25 Q3 FY25 9M FY24 9M FY25 1CLAND| 13
Slide 15: Group Financial Highlights (1/2)
Group Financial Highlights (1/2) (1) Net Worth <1 > Net Worth ROCE (2) / RONW ROCE RONW (3) (3 > (₹ (? Mn) Mn) (%) (%) - A - RoCE RoNW 87,238 88,994 79,587 11% 11% 9% 11% 9% 8% FY23 FY24 9M FY25 FY23 FY24 9M FY25 Capital Expenditure Asset Turnover Ratio <4 )<5 ) Ratio (4)(5) (₹ (? Mn) (x) (X) 3,975
Slide 16: Group Financial Highlights (2/2)
Group Financial Highlights (2/2) Cash and Bank Balances / Net Cash (1) Cash Flow from Operations (₹ Mn) Total Cash ■■Total (₹ (? Mn) (? Net Net Cash 9,968 37,707 37,669 27,189 5,889 24,953 24,122 21,756 3,640 FY23 FY24 9M FY25 FY23 FY24 9M FY25 Net Working Capital (2) Cash Conversion Cycle (CCC) (3)
Slide 17: Thank You
iGiANPl GLAND PHARMA Thank You Investor Relations: Corporate Office Gland Pharma Gland Pharma Limited Sampath Kumar Pallerlamudi Plot No. 11 & 84, TSIIC Phase: IV Company Secretary & Compliance Officer Pashamylaram (V), Patancheru (M), Sangareddy District EY Investor Relations Hyderabad 502307, Tela